538965 — CONCORD DRUGS Income Statement
0.000.00%
Last trade - 00:00
- IN₹365.10m
- IN₹532.15m
- IN₹520.81m
- 69
- 39
- 45
- 50
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 481 | 513 | 514 | 590 | 521 |
Cost of Revenue | |||||
Gross Profit | 84.8 | 87.6 | 91.8 | 169 | 111 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 461 | 495 | 457 | 551 | 491 |
Operating Profit | 19.5 | 18.8 | 56.2 | 38.3 | 29.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4.4 | 4.57 | 42.9 | 22.5 | 12.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4.07 | 3.28 | 32.8 | 15.9 | 9.86 |
Net Income Before Extraordinary Items | |||||
Net Income | 4.07 | 3.28 | 32.8 | 15.9 | 9.86 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 4.07 | 3.28 | 32.8 | 15.9 | 9.86 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.518 | 0.375 | 0.462 | 1.82 | 1.06 |